Alzamend Neuro (NASDAQ:ALZN) Trading Up 0.9% – Here’s What Happened

Posted by Brian Himes on Jun 12th, 2026

Alzamend Neuro, Inc. (NASDAQ:ALZN – Get Free Report) shares were up 0.9% on Wednesday . The stock traded as high as $1.16 and last traded at $1.16. Approximately 41,641 shares traded hands during mid-day trading, a decline of 31% from the average daily volume of 59,984 shares. The stock had previously closed at $1.15.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of Alzamend Neuro from a “sell (e+)” rating to a “sell (e)” rating in a research report on Thursday. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $28.00.

View Our Latest Stock Report on ALZN

Alzamend Neuro Price Performance

The stock’s 50-day moving average price is $1.07 and its 200-day moving average price is $1.69. The company has a market cap of $4.60 million, a P/E ratio of -0.56 and a beta of 0.16.

Alzamend Neuro (NASDAQ:ALZN – Get Free Report) last announced its earnings results on Wednesday, March 11th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.05). As a group, analysts expect that Alzamend Neuro, Inc. will post -2.58 EPS for the current fiscal year.

Insider Activity at Alzamend Neuro

In related news, Director Milton C. Ault III purchased 108,388 shares of the firm’s stock in a transaction that occurred on Tuesday, April 14th. The shares were bought at an average price of $1.00 per share, for a total transaction of $108,388.00. Following the completion of the transaction, the director owned 116,648 shares of the company’s stock, valued at approximately $116,648. This trade represents a 1,312.20% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Insiders own 1.39% of the company’s stock.

Institutional Trading of Alzamend Neuro

A hedge fund recently raised its stake in Alzamend Neuro stock. DRW Securities LLC boosted its holdings in Alzamend Neuro, Inc. (NASDAQ:ALZN – Free Report) by 27.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 116,319 shares of the company’s stock after buying an additional 25,074 shares during the quarter. DRW Securities LLC owned approximately 3.06% of Alzamend Neuro worth $212,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 49.61% of the company’s stock.

About Alzamend Neuro

(Get Free Report)

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.